2017
A Multistrain Mathematical Model To Investigate the Role of Pyrazinamide in the Emergence of Extensively Drug-Resistant Tuberculosis
Fofana MO, Shrestha S, Knight GM, Cohen T, White RG, Cobelens F, Dowdy DW. A Multistrain Mathematical Model To Investigate the Role of Pyrazinamide in the Emergence of Extensively Drug-Resistant Tuberculosis. Antimicrobial Agents And Chemotherapy 2017, 61: 10.1128/aac.00498-16. PMID: 27956422, PMCID: PMC5328532, DOI: 10.1128/aac.00498-16.Peer-Reviewed Original ResearchMeSH KeywordsAntitubercular AgentsBayes TheoremBiological AvailabilityComputer SimulationDrug Administration ScheduleDrug Resistance, Multiple, BacterialExtensively Drug-Resistant TuberculosisFluoroquinolonesHumansMicrobial Sensitivity TestsModels, StatisticalMycobacterium tuberculosisPyrazinamideRifampinTuberculosis, PulmonaryConceptsCompanion drugsExtensively Drug-Resistant TuberculosisSecond-line treatmentFirst-line treatmentSecond-line regimensDrug-resistant tuberculosisUse of pyrazinamideExtensive drug resistanceDrug resistance dataEmergence of strainsEmergence of mutationsXDR-TBSequential regimensHIV infectionAlternative drugsResistance amplificationPyrazinamide resistanceProlonged treatmentCombination antimicrobialsDrug resistanceInfectious diseasesPrevalenceProportion of simulationsAppropriate useRegimens
2010
Development of Extensively Drug-resistant Tuberculosis during Multidrug-resistant Tuberculosis Treatment
Shin SS, Keshavjee S, Gelmanova IY, Atwood S, Franke MF, Mishustin SP, Strelis AK, Andreev YG, Pasechnikov AD, Barnashov A, Tonkel TP, Cohen T. Development of Extensively Drug-resistant Tuberculosis during Multidrug-resistant Tuberculosis Treatment. American Journal Of Respiratory And Critical Care Medicine 2010, 182: 426-432. PMID: 20413630, PMCID: PMC2921603, DOI: 10.1164/rccm.200911-1768oc.Peer-Reviewed Original ResearchConceptsMDR-TB treatmentXDR-TBDrug-resistant tuberculosisMultidrug-resistant (MDR) TBMDR-TB treatment programmeExtensively Drug-Resistant TuberculosisMultidrug-resistant tuberculosis treatmentCox proportional hazards modelDevelopment of XDRMDR-TB therapyTB treatment servicesAmplification of resistanceProportional hazards modelThreefold increaseMDR-TBCavitary lesionsConsecutive patientsAppropriate therapyClinical outcomesTreatment adherenceTuberculosis treatmentInjectable antibioticsTimely initiationPrescribed drugsRetrospective analysis